Targeted development of AMPK ?2-isoform allosteric activators

AMPK ?2-异构体变构激活剂的靶向开发

• 批准号: nhmrc : 1145265
• 负责人: Dr Jon Oakhill
• 金额: $ 60.73万
• 依托单位: St. Vincent's Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-development-ampk-allosteric-activators/1320406
• 关键词: Targeted; development; AMPK; isoform; allosteric

Sedentary lifestyles and consumption of high energy foods has led to dramatic increases in the incidence of diseases associated with metabolic dysregulation e.g. type 2 diabetes. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as a cellular fuel gauge. We have discovered a new drug that crucially activates the form of AMPK found in metabolically active organs. We aim to develop this drug to unlock new therapeutic opportunity.

久坐不动的生活方式和高能量食物的消费导致与代谢失调相关的疾病（例如2型糖尿病）的发病率急剧增加。治疗这些疾病的一个有吸引力的药物靶点是AMP活化蛋白激酶（AMPK），它起着细胞燃料计量器的作用。我们发现了一种新药，它能激活代谢活跃器官中的AMPK。我们的目标是开发这种药物，以释放新的治疗机会。